Gazelle® for Point of Care Testing (POCT) identifies Beta Thalassemia Rapidly, easily and inexpensively.
Hemex’s Gazelle™ provides affordable and accurate Beta Thalassemia screening to populations which located at sites where it is needed most. Hemex innovates by designing Gazelle, a product that listens the need of healthcare providers including those located in remote and challenging settings. Initial test includes Beta Thalassemia detection as one of the hemoglobin disorders (hemoglobinopathy).
More than 6% of the world’s population are at risk of inheriting hemoglobin disorder, including Beta Thalassemia. In Indonesia, there are approximately 3% of Thalassemia patients and the prevalence increases every year. Thalassemia is a hereditary disease, early diagnosis can prevent tens of thousands of child deaths each year.
Gazelle Hb Variant is a miniaturized version of the gold standard testing known as electrophoresis. Performing the test does not require an expert and only requires minimal training. Results are displayed in 8 minutes, including the quantification of each hemoglobin type (HbA, HbF and Hb S, Hb A2/C/E). The results can be stored locally or transferred to the cloud to allow patient and disease tracking.
We are fully committed to being reliable solution and partner,
focused on helping you enhance your healthcare services